Consumer products containing cannabis-derived CBN to be banned from June

Dansk

A revised ordinance will ban consumer products containing cannabis-derived CBN starting in June. Only patients with specific conditions, such as intractable diseases without alternative treatments, will be allowed to use them.

The Japan Times reports that under a revised ordinance from the Ministry of Health, Labour and Welfare (MHLW), consumer products containing CBN—a substance derived from cannabis—will be banned starting in June. Access will be restricted to patients with specific conditions, such as intractable diseases with no alternative treatment options. The article, published on March 19, 2026, lists keywords including drugs, MHLW, CBN, and marijuana. This policy targets consumer products while preserving limited medical applications.

Relaterede artikler

Illustration of Anvisa approving medical cannabis cultivation in Brazil, featuring scientists in a lab with plants and official documents.
Billede genereret af AI

Anvisa approves cannabis cultivation for medical purposes

Rapporteret af AI Billede genereret af AI

The National Health Surveillance Agency (Anvisa) approved, on January 28, 2026, resolutions allowing cannabis cultivation for health treatments and research, along with new administration routes and plant imports. This step marks progress in the national production chain, easing access to plant-derived medicines. The changes broaden options for patients with severe illnesses while upholding strict restrictions.

Review uncovers limited benefits of medical cannabis

A comprehensive analysis of over 2,500 studies shows that medical cannabis has strong evidence for only a few specific uses, despite widespread public belief in its broader effectiveness. Led by UCLA Health researchers, the review highlights gaps between perceptions and scientific proof for conditions like chronic pain and anxiety. It also identifies potential risks, particularly for adolescents and daily users.

Review shows limited cannabis benefits for chronic pain

Rapporteret af AI

A comprehensive review of clinical trials suggests that cannabis products high in THC may provide modest, short-term relief for chronic pain, especially neuropathic types, but with notable side effects. In contrast, CBD-dominant products offer no clear advantages. Researchers call for more long-term studies to assess safety and efficacy.

Sundhed

Cannabis compounds CBD and THC show targeted effects against ovarian cancer cells in lab study

Sundhed

Study shows cannabis drinks halve alcohol use

Sundhed

Large study finds no evidence cannabis treats anxiety, depression or PTSD

Supreme Court questions gun ban for marijuana users

The U.S. Supreme Court heard arguments in United States v. Hemani, challenging a federal law that prohibits unlawful drug users from possessing firearms. Justices from both conservative and liberal sides expressed skepticism about the statute's broad application, particularly to marijuana users. The case stems from a 2022 incident involving Ali Danial Hemani, who was convicted after admitting to frequent marijuana use.

Colorado audit finds many cannabis flower THC labels overstated; concentrates largely accurate

Rapporteret af AI Faktatjekket

A statewide analysis led by the University of Colorado Boulder found that about 43% of cannabis flower products sold in Colorado listed THC levels outside the state’s ±15% accuracy threshold—most overstating potency—while 96% of concentrates matched their labels. The results point to a need for tighter testing and clearer packaging to bolster consumer trust.

South Korean PM vows measures to tighten safety rules on chemical products

Prime Minister Kim Min-seok said on Thursday, January 15, 2026, that the government will implement thorough measures to bolster safety rules on chemical goods, citing the long-running consumer goods disaster over toxic humidifier disinfectant. He emphasized that ensuring the safety and health of the people is the government's top policy priority.

Tobacco plants engineered to produce five psychedelic drugs

Rapporteret af AI

Scientists at the Weizmann Institute of Science in Israel have modified tobacco plants to produce five powerful psychedelic compounds typically found in mushrooms, plants, and toads. The technique uses temporary genetic changes to create a sustainable source for research and potential medicines. Experts say this could simplify production compared to chemical synthesis or harvesting from nature.

torsdag d. 2. april 2026, 06.58

Hong Kong to impose two-tier penalties for carrying vapes publicly from April 30

lørdag d. 7. marts 2026, 00.08

Two Cincinnati breweries sue over Ohio's THC beverage ban

lørdag d. 14. februar 2026, 20.01

Anti-vaping law implementation progresses slowly

torsdag d. 5. februar 2026, 21.34

Mexico's Supreme Court falls one vote short of easing marijuana possession limit

søndag d. 1. februar 2026, 19.44

Pcpb warns against fake pest control products, 25 arrested

mandag d. 19. januar 2026, 10.45

Cochrane review: Cannabis provides no meaningful relief for neuropathic pain

fredag d. 16. januar 2026, 09.40

Scientists resurrect ancient cannabis enzymes with medical promise

fredag d. 19. december 2025, 09.34

Trump Marijuana Reforms: Executive Order Signed, Advancing Research and Medicare Access

torsdag d. 18. december 2025, 12.13

Trump signs order to ease marijuana regulations

tirsdag d. 18. november 2025, 02.53

Nano-formulated CBD eases neuropathic pain in mice without motor or memory side effects

 

 

 

Dette websted bruger cookies

Vi bruger cookies til analyse for at forbedre vores side. Læs vores privatlivspolitik for mere information.
Afvis